The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers are Not Associated with Severe COVID-19 Infection in a Multi-Site UK Acute Hospital Trust
Open accessPublished version of a preprint
Abstract
Aims: The SARS-CoV-2 virus binds to the angiotensin-converting enzyme 2 (ACE2) receptor for cell entry. It has been suggested that angiotensin-converting enzyme inhibitors (ACEi) and angiotensin II receptor blockers (ARB), which are commonly used in patients with hypertension or diabetes and may raise tissue ACE2 levels, could increase the risk of severe COVID-19 infection. Methods and results: We evaluated this hypothesis in a consecutive cohort of 1200 acute inpatients with COVID-19 at two hospitals with a multi-ethnic catchment population in London (UK). The mean age was 68 ± 17 years (57% male) and 74% of patients had at least one comorbidity. Overall, 415 patients (34.6%) reached the primary endpoint of death or transfer to a critical care unit for organ support within 21 days of symptom onset. A total of 399 patients (33.3%) were taking ACEi or ARB. Patients on ACEi/ARB were significantly older and had more comorbidities. The odds ratio for the primary endpoint in patients on ACEi and ARB, after adjustment for age, sex and co-morbidities, was 0.63 (95% confidence interval 0.47–0.84, P < 0.01). Conclusions: There was no evidence for increased severity of COVID-19 in hospitalised patients on chronic treatment with ACEi or ARB. A trend towards a beneficial effect of ACEi/ARB requires further evaluation in larger meta-analyses and randomised clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., Xiang, J., Wang, Y., Song, B., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30566-3 · Cited by 27,263
Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N.-H., Nitsche, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.02.052 · Cited by 20,286
Richardson, S., Hirsch, J. S., Narasimhan, M., Crawford, J. M., McGinn, T., Davidson, K. W., and the Northwell COVID-19 Research Consortium, Barnaby, D. P., Becker, L. B., Chelico, J. D., et al. (2020) · JAMA · doi:10.1001/jama.2020.6775 · Cited by 9,254
Grasselli, G., Zangrillo, A., Zanella, A., Antonelli, M., Cabrini, L., Castelli, A., Cereda, D., Coluccello, A., Foti, G., Fumagalli, R., et al. (2020) · JAMA · doi:10.1001/jama.2020.5394 · Cited by 5,469
Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy
Onder, G., Rezza, G., & Brusaferro, S. (2020) · JAMA · doi:10.1001/jama.2020.4683 · Cited by 4,171
A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus–induced lung injury
Kuba, K., Imai, Y., Rao, S., Gao, H., Guo, F., Guan, B., Huan, Y., Yang, P., Zhang, Y., Deng, W., et al. (2005) · Nature Medicine · doi:10.1038/nm1267 · Cited by 3,445
COVID-19 and the cardiovascular system
Zheng, Y.-Y., Ma, Y.-T., Zhang, J.-Y., & Xie, X. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-020-0360-5 · Cited by 2,970
Angiotensin-converting enzyme 2 protects from severe acute lung failure
Imai, Y., Kuba, K., Rao, S., Huan, Y., Guo, F., Guan, B., Yang, P., Sarao, R., Wada, T., Leong-Poi, H., et al. (2005) · Nature · doi:10.1038/nature03712 · Cited by 2,453
Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19
Vaduganathan, M., Vardeny, O., Michel, T., McMurray, J. J. V., Pfeffer, M. A., & Solomon, S. D. (2020) · New England Journal of Medicine · doi:10.1056/nejmsr2005760 · Cited by 2,101
Zhang, P., Zhu, L., Cai, J., Lei, F., Qin, J.-J., Xie, J., Liu, Y.-M., Zhao, Y.-C., Huang, X., Lin, L., et al. (2020) · Circulation Research · doi:10.1161/circresaha.120.317134 · Cited by 1,133
Jackson, R., Kartoglu, I., Stringer, C., Gorrell, G., Roberts, A., Song, X., Wu, H., Agrawal, A., Lui, K., Groza, T., et al. (2018) · BMC Medical Informatics and Decision Making · doi:10.1186/s12911-018-0623-9 · Cited by 134
Self-citation
Research works printed but not linked: 16
- Guan, 2020, Clinical characteristics of coronavirus disease 2019 in China, N Engl J Med, 382, 1708, 10.1056/NEJMoa2002032 · DOI · Paper page
- Vuille-dit-Bille, 2015, Human intestine luminal ACE2 and amino acid transporter expression increased by ACE-inhibitors, Amino Acids, 47, 693, 10.1007/s00726-014-1889-6 · DOI · Paper page
- Kuster, 2020, SARS-CoV2: should inhibitors of the renin-angiotensin system be withdrawn in patients with COVID-19?, Eur Heart J, 41, 1801, 10.1093/eurheartj/ehaa235 · DOI · Paper page
- Tomasoni, 2020, COVID-19 and heart failure: from infection to inflammation and angiotensin II stimulation. Searching for evidence from a new disease, Eur J Heart Fail, 22, 957, 10.1002/ejhf.1871 · DOI · Paper page
- Danser, 2020, Renin-angiotensin system blockers and the COVID-19 pandemic: at present there is no evidence to abandon renin-angiotensin system blockers, Hypertension, 75, 1382, 10.1161/HYPERTENSIONAHA.120.15082 · DOI · Paper page
- Bean, 2019, Semantic computational analysis of anticoagulation use in atrial fibrillation from real world data, PLoS One, 14, 10.1371/journal.pone.0225625 · DOI
- Kraljevic, 2019, MedCAT – medical concept annotation tool, arXiv
- Johnson, 2016, MIMIC-III, a freely accessible critical care database, Sci Data, 3, 10.1038/sdata.2016.35 · DOI · Paper page
- Linden, 2020, Conducting sensitivity analysis for unmeasured confounding in observational studies using E-values: the evalue package, Stata J, 20, 162, 10.1177/1536867X20909696 · DOI
- Li, 2020, Association of renin-angiotensin system inhibitors with severity or risk of death in patients with hypertension hospitalized for coronavirus disease 2019 (COVID-19) infection in Wuhan, China, JAMA Cardiol, 10.1001/jamacardio.2020.1624 · DOI · Paper page
- Mancia, 2020, Renin-angiotensin-aldosterone system blockers and the risk of Covid-19, N Engl J Med, 382, 2431, 10.1056/NEJMoa2006923 · DOI · Paper page
- Julius, 2004, Cardiovascular risk reduction in hypertensive black patients with left ventricular hypertrophy: the LIFE study, J Am Coll Cardiol, 43, 1047, 10.1016/j.jacc.2003.11.029 · DOI
- Taylor, 2005, Should ethnicity serve as the basis for clinical trial design? Importance of race/ethnicity in clinical trials: lessons from the African-American Heart Failure Trial (A-HeFT), the African-American Study of Kidney Disease and Hypertension (AASK), and the Antihypertensive and lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), Circulation, 112, 3654, 10.1161/CIRCULATIONAHA.105.540443 · DOI
- Reynolds, 2020, Renin-angiotensin-aldosterone system inhibitors and risk of Covid-19, N Engl J Med, 382, 2441, 10.1056/NEJMoa2008975 · DOI · Paper page
- Sama, 2020, Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin-angiotensin-aldosterone inhibitors, Eur Heart J, 41, 1810, 10.1093/eurheartj/ehaa373 · DOI · Paper page
- de Simone, 2020, Position statement of the ESC Council on Hypertension on ACE-inhibitors and angiotensin receptor blockers
Cited by
Collider bias undermines our understanding of COVID-19 disease risk and severity
Griffith, G. J., Morris, T. T., Tudball, M. J., Herbert, A., Mancano, G., Pike, L., Sharp, G. C., Sterne, J., Palmer, T. M., Davey Smith, G., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19478-2 · Cited by 826
de Abajo, F. J., Rodríguez-Martín, S., Lerma, V., Mejía-Abril, G., Aguilar, M., García-Luque, A., Laredo, L., Laosa, O., Centeno-Soto, G. A., Ángeles Gálvez, M., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31030-8 · Cited by 408
Lopes, R. D., Macedo, A. V. S., de Barros E Silva, P. G. M., Moll-Bernardes, R. J., dos Santos, T. M., Mazza, L., Feldman, A., D’Andréa Saba Arruda, G., de Albuquerque, D. C., Camiletti, A. S., et al. (2021) · JAMA · doi:10.1001/jama.2020.25864 · Cited by 364
Tajbakhsh, A., Gheibi Hayat, S. M., Taghizadeh, H., Akbari, A., inabadi, M., Savardashtaki, A., Johnston, T. P., & Sahebkar, A. (2021) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2020.1822737 · Cited by 272
Shah, H., Khan, M. S. H., Dhurandhar, N. V., & Hegde, V. (2021) · Acta Diabetologica · doi:10.1007/s00592-020-01636-z · Cited by 80
Metadata
- Authors
- Bean, D. M., Kraljevic, Z., Searle, T., Bendayan, R., Kevin, O., Pickles, A., Folarin, A., Roguski, L., Noor, K., Shek, A., Zakeri, R., Shah, A. M., Teo, J. T. H., & Dobson, R. J. B.
- Venue
- European Journal of Heart Failure
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-06-01
- Volume
- 22
- Issue
- 6
- Pages
- 967-974
- ISSN
- 1388-9842 (ISSN-L)
- 1879-0844
- OpenAlex
- W3030177929
- Cited by
- 229
- References
- 11
- FWCI
- 6.61
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.